Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
IPO Year: 2014
Exchange: NYSE
Website: nevro.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/9/2024 | Sell → Neutral | Citigroup | |
8/8/2024 | Underperform → Peer Perform | Wolfe Research | |
8/7/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
8/7/2024 | Neutral → Underweight | JP Morgan | |
8/7/2024 | $13.00 → $5.50 | Equal Weight → Underweight | Wells Fargo |
5/22/2024 | $13.50 → $9.00 | Neutral → Sell | Citigroup |
2/22/2024 | Outperform → Perform | Oppenheimer | |
1/12/2024 | $23.00 → $20.00 | Outperform → Sector Perform | RBC Capital Mkts |
12/21/2023 | $23.00 | Buy → Hold | Canaccord Genuity |
7/19/2023 | $26.00 | Neutral | Robert W. Baird |
Truist Securities analyst Richard Newitter maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $11 to $10.
Across the recent three months, 6 analysts have shared their insights on Nevro (NYSE:NVRO), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 3 1 2 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 1 2M Ago 0 0 0 0 1 3M Ago 0 0 2 1 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.37, with a high estimate of $13.00 and a low estimate of $8.20. A negative shift in s
Morgan Stanley analyst Cecilia Furlong maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $14 to $9.
Citigroup analyst Joanne Wuensch maintains Nevro (NYSE:NVRO) with a Sell and lowers the price target from $9 to $8.2.
Citigroup analyst Joanne Wuensch downgrades Nevro (NYSE:NVRO) from Neutral to Sell and lowers the price target from $13.5 to $9.
9 analysts have shared their evaluations of Nevro (NYSE:NVRO) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 8 1 0 Last 30D 0 0 2 1 0 1M Ago 0 0 3 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 2 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.89, a high estimate of $19.00, and a low estimate of $11.00. Highlighting a 17.28% decrease, the curre
Canaccord Genuity analyst William Plovanic maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $17 to $11.
Wells Fargo analyst Nathan Treybeck maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $14 to $13.
Piper Sandler analyst Adam Maeder maintains Nevro (NYSE:NVRO) with a Underweight and lowers the price target from $15 to $12.
Nevro is raising its adjusted EBITDA guidance for the full-year 2024 to a range of negative $5 million to positive $2 million from its previous guidance range of negative $14 million to negative $8 million. For the second quarter of 2024, the company expects worldwide revenue to be in the range of approximately $106 million to $108 million and adjusted EBITDA to be in the range of negative $3.5 million to negative $2.5 million.
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif., Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (P
REDWOOD CITY, Calif., Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on October 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induce
REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For th
HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real time* REDWOOD CITY, Calif., Sept. 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX iQ™ with HFX AdaptivAI™ – a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system. Building on a foundation of landmark evidence2, cli
REDWOOD CITY, Calif., Sept. 19, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on September 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 51,543 shares of Nevro's common stock to 21 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induc
REDWOOD CITY, Calif., Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Wells Fargo 2024 Healthcare Conference on Friday, September 6, 2024, beginning at 8:45 a.m. EDT. A live webcast of the session and a replay of the webcast will be available on the Events and Presentations page in the Investors section of the company's website at www.nevro.com. Internet Posting of Information Nevro routinely posts information that may be important to in
REDWOOD CITY, Calif., Aug. 14, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on August 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 10,199 shares of Nevro's common stock to four new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induce
Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second-quarter 2024 financial results, revised its full-year 2024 guidance, and issued third-quarter 2024 guidance. The company also announced that it is initiating a process
REDWOOD CITY, Calif., July 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on July 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 69,201 shares of Nevro's common stock to 17 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material inducement
REDWOOD CITY, Calif., July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For thos
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13D/A - NEVRO CORP (0001444380) (Subject)
SC 13G - NEVRO CORP (0001444380) (Subject)
SC 13G - NEVRO CORP (0001444380) (Subject)
SC 13G - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi
REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately. "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and
REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately. "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a
S-8 - NEVRO CORP (0001444380) (Filer)
8-K - NEVRO CORP (0001444380) (Filer)
10-Q - NEVRO CORP (0001444380) (Filer)
SD - NEVRO CORP (0001444380) (Filer)
8-K - NEVRO CORP (0001444380) (Filer)
8-K - NEVRO CORP (0001444380) (Filer)
10-Q - NEVRO CORP (0001444380) (Filer)
8-K - NEVRO CORP (0001444380) (Filer)
8-K - NEVRO CORP (0001444380) (Filer)
DEFA14A - NEVRO CORP (0001444380) (Filer)
REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For th
Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second-quarter 2024 financial results, revised its full-year 2024 guidance, and issued third-quarter 2024 guidance. The company also announced that it is initiating a process
REDWOOD CITY, Calif., July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For thos
Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christoforou to Chief Operating Officer REDWOOD CITY, Calif., May 7, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results. The company also announced additional restructuring steps to advance its strategy and accelerate profitability, raised its adjusted EBITDA guidance and reaffirmed its revenue guidance for the full-year 2024, and
REDWOOD CITY, Calif., April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For those
Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results. The company also provided first-quarter and full-year 2024 financial guidance. "Our fourth quarter performance reflects continued execution of our three-pillar strategy initiated in the second quarter of 2023," said Kevin Thornal, Nevro's CEO and president. "The actions we have taken, including our commercial realignment, strengthening our executive team with talented and e
REDWOOD CITY, Calif., Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024. The company will also host a conference call on February 21, 2024 to discuss its financial results. The call will begin at 1:30 pm PT / 4:30 pm ET. Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240) 789-2728 internationally, using conference ID: 3583097. A
Company to Host Conference Call on Wednesday, November 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., Oct. 4, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2023 after the market closes on November 1, 2023. Management will host a conference call on November 1, 2023 to discuss third quarter 2023 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET. Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S.
Company Takes Proactive Steps to Improve Commercial Execution and Maximize Growth Opportunities REDWOOD CITY, Calif., Aug. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second quarter 2023 financial results. The company also provided third quarter guidance and updated its full-year 2023 guidance. Recent Business Highlights and Guidance Second Quarter 2023 Worldwide Revenue of $108.8 Million Grew 4% As Reported and Constant Currency Compared to Second Quarter 2022Painful Diabetic Neuropathy (PDN) Indication Sales of Approximately $19.0 Million Grew
Company to Host Conference Call on Tuesday, August 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., June 27, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the second quarter ended June 30, 2023 after the market closes on August 1, 2023. Management will host a conference call on August 1, 2023 to discuss second quarter 2023 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET. Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240
Citigroup upgraded Nevro from Sell to Neutral
Wolfe Research upgraded Nevro from Underperform to Peer Perform
JMP Securities downgraded Nevro from Mkt Outperform to Mkt Perform
JP Morgan downgraded Nevro from Neutral to Underweight
Wells Fargo downgraded Nevro from Equal Weight to Underweight and set a new price target of $5.50 from $13.00 previously
Citigroup downgraded Nevro from Neutral to Sell and set a new price target of $9.00 from $13.50 previously
Oppenheimer downgraded Nevro from Outperform to Perform
RBC Capital Mkts downgraded Nevro from Outperform to Sector Perform and set a new price target of $20.00 from $23.00 previously
Canaccord Genuity downgraded Nevro from Buy to Hold and set a new price target of $23.00
Robert W. Baird initiated coverage of Nevro with a rating of Neutral and set a new price target of $26.00